Since the publication of The Hallmarks of Aging in 2013, aging research has exploded. The field now has more than 300,000 articles on the biological signals of the effect of time on the body. What would Marty McFly, the legendary character from the Back to the Future saga who traveled with his DeLorean time machine from the ‘80s to the ‘50s, think if he visited 2024 and saw laboratories experimenting with techniques to turn back the biological clocks of cells or increase the lifespan of rejuvenated mice?
Neurocrine Biosciences Inc.’s top-line phase II data, though billed as promising, wasn’t enough to please observers on Wall Street, who stacked the data in schizophrenia with NBI-1117568 (NBI-'568) against others in the space. Shares (NASDAQ:NBIX) closed Aug. 28 at $123.76, down $28.79, or 18.9%.
A patent from Centre National de la Recherche Scientifique (CNRS), McGill University and Sorbonne University discloses new acetylcholinesterase (AChE) inhibitors reported to be useful for the treatment of substance abuse and dependence, obsessive-compulsive disorder, anorexia nervosa, bulimia nervosa, obesity, Parkinson’s and Alzheimer’s disease.
Mutations in the GNAO1 gene are tied to neurological disorders characterized by movement abnormalities and developmental delay. GNAO1 encodes the protein guanine nucleotide-binding protein G(o) subunit α, which is highly expressed in the brain. Among the mutations, R209H results in dystonia, choreoathetosis and developmental delay without seizures.
Restoring glucose metabolism in astrocytes, which is impaired in Alzheimer’s disease (AD), has a direct effect on neurons, which replenish their fuel supply and resume synaptic activity. A group of scientists from Stanford University School of Medicine has revealed the pathway that explains where this efflux is interrupted and which molecules restore it in mouse models with amyloid and tau pathology. Their findings could help prevent the progression of this neurodegenerative disease.
Work at DE Shaw Research LLC has led to the identification of bicyclic imide compounds acting as transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists.
Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro (UFRJ) have jointly patented new sodium channel protein type 9 subunit α (SCN9A; Nav1.7) and/or SCN10A (Nav1.8) blockers reported to be useful for the treatment of pain.
All patients dosed in a phase IIa trial with Tryptamine Therapeutics Ltd.’s (Tryp) oral psilocybin (TRP-8802) trial reported an improvement in fibromyalgia pain severity, sleep, and pain interference.
UCB SA is divesting its mature neurology and allergy business in China, selling those products to CBC Group and Mubadala Investment Co. for $680 million so it can refocus on innovation and partnerships in China. The deal includes UCB’s manufacturing site in Zhuhai in Guangdong province.
Researchers from Case Western Reserve University and the U.S. Department of Veterans Affairs, continue their development of a neuroprosthetic which comprises a system of implanted or wearable sensors.
RSS
